Compare Mesoblast Limited (MESO) vs Texas Instruments Incorporated (TXN) Price & Performance

MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.

Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.

Texas Instruments (TXN) trades at $284.07, showing minimal daily movement (+0.02%). The stock demonstrates strong profitability with 29.11% net margins and 32.18% ROE, though valuation metrics appear elevated with a P/E of 48.55. Recent Q1 2026 earnings beat expectations at $1.68 EPS versus $1.36 expected, while technical indicators show bearish momentum despite crossing above the 20-day moving average according to Zacks (June 3, 2026).

The company faces mixed signals with improving operational cash flow ($7.15B in 2025) and AI-driven demand growth offset by declining profit margins and rising debt levels. Analyst consensus remains positive with a $317.20 price target, though technical weakness and competitive pressures in semiconductors present near-term headwinds for shareholders.